tags: [potential/short, analyst/fiat-lux-partners, analyst/glasshouse-research] ...

Something dubious about this: short seller vs anonymous rebuttal group.

GlassHouse Research published on Catalent Inc (NYSE: CTLT — $8.04 billion), a developer and distributor of biologics and consumer health products. GlassHouse called Catalent “a deteriorating company propped up with accounting gimmicks.” For example, GlassHouse highlighted that the company changed its revenue recognition policy and then began realizing high amounts of premature revenue. In addition, GlassHouse highlighted high executive turnover, Catalent’s one-time pandemic benefit, and “one of the lowest balances of insider ownership ever reported.”

Fiat Lux Partners, an anonymous group that “calls out weak short activism,” issued a rebuttal to GlassHouse research on Catalent Inc (NYSE: CTLT — $8.90 billion), a developer and distributor of biologics and consumer health products. Fiat Lux wrote that GlassHouse’s report, “represents a one-dimensional application of a boilerplate ‘forensic accounting’ checklist which, in many cases, ignores or fails to address important contextual information.”

Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Its Biologics segment provides development and manufacturing for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene therapies. Its Softgel and Oral Technologies segment provide formulation, development, and manufacturing services for soft capsules, as well as large-scale manufacturing of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. Its Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for, drugs, biologics and clinical trials.